Last reviewed · How we verify
ICAR19 CAR-T cells
At a glance
| Generic name | ICAR19 CAR-T cells |
|---|---|
| Also known as | Biological drug |
| Sponsor | Immune Cell, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICAR19 CAR-T cells CI brief — competitive landscape report
- ICAR19 CAR-T cells updates RSS · CI watch RSS
- Immune Cell, Inc. portfolio CI